Prognosis of EBV Infection in Children with Tonsillitis

Aims: Determining the prognosis of Epstein-Barr virus (EBV) infection with in children with tonsillitis.

Methods: Totally 102 children with chronic tonsillitis admitted to our hospital between January 2017 and March 2019 were selected. Among them, 52 children with EBV infection were assigned to a case group, and the other 50 without EBV infection to a control group. All children were given targeted therapy. Then the two groups were compared in efficacy, defervescence time, alleviation time of tonsillar enlargement and pharyngalgia after therapy, immune function-associated indexes and inflammatory factor-associated indexes before and after therapy, incidence of adverse reactions during therapy, and recurrence times during therapy and 1-year follow-up.

Results: Compared with the case group, the control group showed notably better efficacy, experienced notably shorter alleviation time of tonsillar enlargement and pharyngalgia, and presented better improvement in immune function and inflammation (all P<0.05). Additionally, the two groups were not greatly different in the incidence of adverse reactions (P>0.05), while the control group experienced notably less times of recurrence during therapy and 1-year follow-up (P<0.05).

Conclusion: EBV infection will compromise the efficacy on children with tonsillitis and take its toll on their prognosis, so it is imperative to adopt a targeted and individualized therapeutic regimen for children with both diseases.